Oncology

The Long View: Survivorship and Follow-Up

At a Glance

Survivorship for rare ovarian cancer requires a highly personalized long-term monitoring plan. Depending on your specific tumor subtype, your care team will track unique blood tumor markers and conduct regular imaging to watch for recurrence, which can sometimes happen years later.

Entering the “survivorship” phase of a rare ovarian cancer diagnosis brings a shift in focus. Unlike the common high-grade serous type, which often follows a predictable early monitoring path, rare ovarian cancers require a more tailored, often long-term surveillance strategy ^[1]^[2]. Because many of these tumors grow slowly or have unique “signals” (markers) they release into the blood, your follow-up plan will be specific to your tumor’s biology ^[3]^[4].

Your Surveillance Schedule

Most major guidelines (NCCN/ESMO) recommend a schedule that is more frequent in the first two years and then gradually spaces out. However, it is critical to know that this is a general guideline; your exact timeline will be heavily personalized based on your specific tumor stage and grade. For some rare types like Adult Granulosa Cell Tumors (AGCT), monitoring may need to continue indefinitely due to the risk of “late recurrence”—sometimes 10 to 20 years later ^[5]^[6]^[7].

Timing	Physical Exam & Symptoms	Blood Tumor Markers	Imaging (CT/MRI/US)
Years 1–2	Every 3–4 months	Every 3–4 months	Every 6–12 months (or as needed) ^[1]
Years 3–5	Every 6 months	Every 6 months	Annually or based on symptoms ^[8]
Year 5+	Annually	Annually	Based on clinical suspicion ^[7]

Monitoring Your Specific “Signals”

A critical part of your follow-up is tracking tumor markers—substances found in your blood that can increase if the cancer returns. While CA-125 is the standard for common ovarian cancer, it is often less reliable for rare types ^[9]^[10].

Germ Cell Tumors: Doctors typically track AFP (Alpha-fetoprotein) and hCG (Human chorionic gonadotropin). Relapses here most often occur within the first two years ^[11]^[12].
Sex Cord-Stromal (e.g., Granulosa Cell): Inhibin B is the most sensitive marker for these tumors ^[13]^[14]. Because these tumors can recur very late, keeping a long-term log of these numbers is vital ^[7].
Low-Grade Serous (LGSOC): While CA-125 is often used, it may not be as sensitive as it is in high-grade cases. Monitoring focuses heavily on physical exams and regular imaging (CT scans) ^[10]^[8].
Mucinous and Clear Cell: Markers like CEA or CA 19-9 may be used for Mucinous types, while Clear Cell may use CA-125, though imaging often plays a larger role due to marker variability ^[15]^[16].

Long-Term Considerations in Survivorship

The “tailored” nature of rare ovarian cancer care extends into the side effects and lifestyle impacts of long-term management.

Hormonal Therapy Impact: Many patients with LGSOC or Granulosa Cell Tumors remain on hormone maintenance therapy (like letrozole) for years to prevent recurrence ^[17]^[18]. While effective, this can lead to long-term side effects like joint pain or decreased bone density, requiring proactive care ^[17].
Fertility and Monitoring: If you had fertility-sparing surgery, surveillance includes regular pelvic ultrasounds to monitor the remaining ovary ^[19]^[20]. While many patients go on to have healthy pregnancies, the initial 2-year window is a period of high clinical suspicion ^[12].
Managing “Scanxiety”: Chronic monitoring for a rare disease can create significant emotional stress. Knowing your specific recurrence risk timeline—for instance, that Germ Cell relapses are rare after two years, while Granulosa Cell relapses can be very late—can help you and your team develop a mental health plan alongside your medical one ^[12]^[6].

The goal of survivorship is not just to wait for the cancer to come back, but to live well while maintaining a high level of “clinical suspicion” that ensures any changes are caught early ^[2]^[7]. You can always revisit the foundational information in When Ovarian Cancer is Rare to remind yourself of your unique journey.

Common questions in this guide

How often will I need follow-up appointments for a rare ovarian cancer?

In the first two years, you will typically have physical exams and blood tests every 3 to 4 months, along with imaging every 6 to 12 months. This schedule gradually spaces out to every 6 months, and eventually annually, depending on your specific tumor type and risk of recurrence.

Which tumor markers will my doctor track during my follow-up?

The markers depend on your specific tumor type. Germ cell tumors are tracked using AFP and hCG, while granulosa cell tumors often release Inhibin B. Low-grade serous, mucinous, and clear cell tumors may use markers like CA-125, CEA, or CA 19-9.

Can rare ovarian cancers come back after five years?

Yes, certain rare types, such as adult granulosa cell tumors, carry a risk of late recurrence even 10 to 20 years after initial treatment. Because of this, some patients require indefinite, long-term monitoring to ensure any changes are caught early.

How does long-term hormone therapy affect my body during survivorship?

Many patients take hormone maintenance therapies like letrozole for years to prevent recurrence. While effective, these medications can cause long-term side effects such as joint pain and decreased bone density, which require proactive management and monitoring.

What happens during follow-up if I had fertility-sparing surgery?

If you had surgery that preserved your fertility, your monitoring will include regular pelvic ultrasounds to carefully check your remaining ovary. The first two years are monitored especially closely to watch for any signs of recurrence.

Curated prompts to bring to your next appointment.

1.Based on my specific subtype, which tumor markers will we track, and what 'baseline' number are we looking for?
2.If I am on long-term hormonal therapy (like letrozole), how will we monitor my bone density or other side effects over the next several years?
3.Since some rare tumors can recur very late, will we continue monitoring beyond the standard five-year mark?
4.If we performed fertility-sparing surgery, how often do I need pelvic ultrasounds to check the remaining ovary?
5.At what point would you recommend a CT scan versus just checking my blood markers and doing a physical exam?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (20)

1
NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.
Armstrong DK, Alvarez RD, Backes FJ, et al.
Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(9)):972-980.
PMID: 36075393
2
ESGO-SIOPE guidelines for the management of adolescents and young adults with non-epithelial ovarian cancers.
Sessa C, Schneider DT, Planchamp F, et al.
The Lancet. Oncology 2020; (21(7)):e360-e368 doi:10.1016/S1470-2045(20)30091-7.
PMID: 32615119
3
Sertoli-Leydig cell tumor of ovary in children: A report of two cases, including retiform variant.
Sarkar P, Sengupta M, Chatterjee U, Ghosh D
Indian journal of pathology & microbiology 2021; (64(3)):559-562 doi:10.4103/IJPM.IJPM_443_20.
PMID: 34341273
4
Germ Cell Tumors of the Female Genital Tract.
Euscher ED
Surgical pathology clinics 2019; (12(2)):621-649 doi:10.1016/j.path.2019.01.005.
PMID: 31097117
5
Recurrent Granulosa Cell Tumor in a Postmenopausal Woman: A Case Report and Literature Review.
Dolkar T, Rayapureddy AK, Kadakia N, et al.
Cureus 2023; (15(8)):e43368 doi:10.7759/cureus.43368.
PMID: 37700975
6
Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary.
Färkkilä A, Haltia UM, Tapper J, et al.
Annals of medicine 2017; (49(5)):435-447 doi:10.1080/07853890.2017.1294760.
PMID: 28276867
7
Late retroperitoneal recurrence of adult-type ovarian granulosa cell tumors: Two case reports and literature review.
Wang Y, Liu T, Deng X, Sun S
Science progress 2025; (108(3)):368504251376404 doi:10.1177/00368504251376404.
PMID: 40906083
8
Low-grade serous ovarian cancer: State of the science.
Slomovitz B, Gourley C, Carey MS, et al.
Gynecologic oncology 2020; (156(3)):715-725 doi:10.1016/j.ygyno.2019.12.033.
PMID: 31969252
9
Quantitative proteomics identifies conserved proteins and altered regulation of mucin-16 in low grade serous ovarian cancers.
Tarney CM, Mhawech-Fauceglia P, Ogata JD, et al.
Clinical proteomics 2025; (22(1)):33 doi:10.1186/s12014-025-09557-1.
PMID: 41053579
10
Low-Grade Serous Carcinoma of the Ovary: The Current Status.
Babaier A, Mal H, Alselwi W, Ghatage P
Diagnostics (Basel, Switzerland) 2022; (12(2)) doi:10.3390/diagnostics12020458.
PMID: 35204549
11
15-Year-Old Patient with an Unusual Alpha-Fetoprotein-Producing Sertoli-Leydig Cell Tumor of Ovary.
Serife K, Karampelas S, Hottat N, et al.
Case reports in obstetrics and gynecology 2022; (2022()):4759826 doi:10.1155/2022/4759826.
PMID: 35450124
12
Obstetric Results after Fertility-Sparing Management of Non-Epithelial Ovarian Cancer.
Piątek S, Szymusik I, Sobiczewski P, et al.
Cancers 2023; (15(16)) doi:10.3390/cancers15164170.
PMID: 37627198
13
Ovarian sclerosing stromal tumor mimicking malignancy: case series and literature review.
Skuk E, Cvjetićanin B, Pirš B, et al.
Archives of gynecology and obstetrics 2024; (310(2)):1171-1177 doi:10.1007/s00404-024-07520-3.
PMID: 38910143
14
Inhibin Alpha Expression in Human Tumors: A Tissue Microarray Study on 12,212 Tumors.
Weidemann S, Noori NA, Lennartz M, et al.
Biomedicines 2022; (10(10)) doi:10.3390/biomedicines10102507.
PMID: 36289769
15
Mucinous Neoplasms of the Ovary: Radiologic-Pathologic Correlation.
Marko J, Marko KI, Pachigolla SL, et al.
Radiographics : a review publication of the Radiological Society of North America, Inc 2019; (39(4)):982-997 doi:10.1148/rg.2019180221.
PMID: 31283462
16
Comparison of the clinical characteristics and prognosis between clear cell carcinomas and high-grade serous ovarian carcinomas.
Dong S, Yu F, Liu Y, et al.
Ginekologia polska 2023; (94(10)):792-798 doi:10.5603/GP.a2022.0123.
PMID: 36477777
17
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
Gershenson DM, Bodurka DC, Coleman RL, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017; (35(10)):1103-1111 doi:10.1200/JCO.2016.71.0632.
PMID: 28221866
18
Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors.
How JA, Legarreta AF, Handley KF, et al.
American journal of obstetrics and gynecology 2024; (230(5)):544.e1-544.e13 doi:10.1016/j.ajog.2024.01.002.
PMID: 38191019
19
Current limits of conservative treatment in ovarian cancer.
Gracia M, Alonso-Espías M, Zapardiel I
Current opinion in oncology 2023; (35(5)):389-393 doi:10.1097/CCO.0000000000000970.
PMID: 37498109
20
Reproductive Outcomes and Fertility Preservation Strategies in Women with Malignant Ovarian Germ Cell Tumors after Fertility Sparing Surgery.
Vasta FM, Dellino M, Bergamini A, et al.
Biomedicines 2020; (8(12)) doi:10.3390/biomedicines8120554.
PMID: 33265938

This page provides general information on survivorship and follow-up care for rare ovarian cancers. Always consult your gynecologic oncologist for a personalized monitoring schedule.

Get notified when new evidence is published on Rare ovarian cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents